Polish Clinical Trials Market Analyzed in New Topical PMR Report Published at MarketPublishers.com15 Aug 2012 • by Natalie Aster
LONDON – Last year, the clinical trials market on which companies carry out phase I-IV clinical trials of drugs and bioequivalence tests was worth around USD 228 million. In comparison with 2010, the value of the market had increased by 7%. The Polish clinical trials market is relatively saturated, and is not expected to see substantial growth, with the estimated annual growth being around 3%-4% during 2012-2013.
Between 2012 and 2014, the Polish clinical trials market is expected to grow at a moderate pace, by around 5% per annum to USD 253.7 million in 2014. This modest increase can also be attributed, to some extent, to the extreme change in the Polish reimbursement system, which has made the operation of the pharmaceutical market in Poland very difficult, particularly for innovative companies. In 2014, however, the situation will improve slightly in the wake of adjustment to the new market conditions and because of the proposed Act on Clinical Trials, which is expected to bring some order to the market.
New market research report “Clinical Trials in Poland 2012” elaborated by PMR has been recently published by Market Publishers Ltd.
Clinical Trials in Poland 2012
Published: June, 2012
Price: US$ 2.800,00
The report offers a complete description of current conditions in the marketplace for clinical trials of drugs and therapies in Poland. It presents the most influential events and trends and analyzes their current and potential effects on the quantity and types of trials conducted by both Polish and multinational companies.
More new market research reports by the publisher can be found at PMR page.